The Role of C-reactive Protein and Procalcitonin in Predicting the Occurrence of Pancreatic Fistula in Patients who Underwent Laparoscopic Pancreaticoduodenectomy: a Retrospective Study

Abstract

Background

The occurrence of postoperative pancreatic fistula following laparoscopic pancreaticoduodenectomy (LPD) is a significant concern, yet there is currently a lack of consensus on reliable predictive methods for this complication. Therefore, the aim of this study was to assess the clinical significance of C-reactive protein (CRP) and procalcitonin (PCT) values and their reliability in early predicting the development of clinically relevant pancreatic fistula (CRPF) following LPD.

Methods

A retrospective analysis was conducted using data from 120 patients who had LPD between September 2019 and December 2021. Preoperative assessment data, standard patients’ demographic and clinicopathological characteristics, intra- and postoperative evaluation, as well as postoperative laboratory values on postoperative days (PODs) 1, 3, and 7, including white blood cells (WBCs), CRP, and PCT, were prospectively recorded on a dedicated database. Two clinicians separately collected and cross-checked all of the data.

Results

Among 120 patients [77 men (64%), 43 women (36%], CRPF occurred in 15 patients (11 grade B and 4 grade C fistulas). The incidence rate of CRPF was 12.3%. A comparison of the median values of WBCs, PCT, and CRP across the two groups revealed that the CRPF group had higher values on most PODs than the non-CRPF group. Receiver operating characteristic (ROC) analysis was used to calculate the area under the curve (AUC) and cutoff values. It was discovered that POD 3 has the most accurate and significant values for WBCs, CRP, and PCT. According to the ROC plots, the AUC for WBCs was 0.842, whereas the AUC for PCT was 0.909. As for CRP, the AUC was 0.941 (95% CI 0.899–0.983, p < 0.01) with a cutoff value of 203.45, indicating a sensitivity of 93.3% and specificity of 91.4%.

Conclusion

Both CRP and PCT can be used to predict the early onset of CRPF following LPD, with CRP being slightly superior on POD 3.

Zusammenfassung

Hintergrund

Das Auftreten einer postoperativen Pankreasfistel nach einer laparoskopischen Pankreatikoduodenektomie (LPD) ist ein erhebliches Problem. Dennoch besteht derzeit kein Konsens über zuverlässige Vorhersagemethoden für diese Komplikation. Ziel dieser Studie war es, die klinische Bedeutung der Werte von C-reaktivem Protein (CRP) und Procalcitonin (PCT) und ihre Zuverlässigkeit bei der frühzeitigen Vorhersage der Entwicklung einer klinisch relevanten Pankreasfistel (CRPF) nach einer LPD zu bewerten.

Methoden

Eine retrospektive Analyse wurde mit Daten von 120 Patienten durchgeführt, die sich zwischen September 2019 und Dezember 2021 einer LPD unterzogen hatten. Präoperative Beurteilungsdaten, demografische und klinisch-pathologische Merkmale von Standardpatienten, intra- und postoperative Bewertung sowie postoperative Laborwerte an postoperativen Tagen (PODs) 1, 3 und 7 einschließlich weißer Blutkörperchen (WBCs), CRP und PCT, wurden prospektiv in einer speziellen Datenbank erfasst. Die Daten wurden von 2 Klinikern, unabhängig voneinander, gesammelt und überprüft.

Ergebnisse

Unter 120 Patienten (77 Männer [64%], 43 Frauen [36%]) trat CRPF bei 15 Patienten auf (11 Fisteln vom Grad B und 4 Fisteln vom Grad C). Die Inzidenzrate von CRPF betrug 12,3%. Ein Vergleich der Medianwerte von WBCs, PCT und CRP in den beiden Gruppen zeigte, dass die CRPF-Gruppe bei den meisten PODs höhere Werte aufwies als die Nicht-CRPF-Gruppe. Zur Berechnung der Fläche unter der Kurve (AUC) und der Grenzwerte wurde eine ROC-Analyse (Receiver Operating Characteristic) angewandt. Es wurde festgestellt, dass POD 3 die genauesten und signifikantesten Werte für Leukozyten, CRP und PCT aufweist. Den ROC-Diagrammen zufolge betrug die AUC für Leukozyten 0,842, während die AUC für PCT 0,909 betrug. Für CRP war die AUC gleich 0,941 (95%-KI 0,899–0,983, p < 0,01) mit einem Cut-off-Wert von 203,45, was einer Sensitivität von 93,3% und einer Spezifität von 91,4% entspricht.

Schlussfolgerung

Sowohl CRP als auch PCT können verwendet werden, um das frühe Einsetzen von CRPF nach LPD vorherzusagen, wobei CRP am POD 3 leicht überlegen ist.

Keywords

laparoscopic pancreaticoduodenectomy - pancreatic fistula - C-reactive protein - Procalcitonin

Schlüsselwörter

laparoskopische Pankreas-Duodenektomie - Pankreasfistel - C-reaktives Protein - Procalcitonin

Publikationsverlauf

Eingereicht: 27. März 2023

Angenommen nach Revision: 21. August 2023

Artikel online veröffentlicht:
05. Oktober 2023

• References

• 1 Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc 1994; 8: 408-410
• 2 Palanivelu C, Jani K, Senthilnathan P. et al. Laparoscopic pancreaticoduodenectomy: technique and outcomes. J Am Coll Surg 2007; 205: 222-230
• 3 Sharpe SM, Talamonti MS, Wang CE. et al. Early national experience with laparoscopic pancreaticoduodenectomy for ductal adenocarcinoma: a comparison of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg 2015; 221: 175-184
• 4 Yan Y, Hua Y, Chang C. et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic and periampullary tumor: A meta-analysis of randomized controlled trials and non-randomized comparative studies. Front Oncol 2023; 12: 1093395
• 5 Ding W, Wu W, Tan Y. et al. The comparation of short-term outcome between laparoscopic and open pancreaticoduodenectomy: a propensity score matching analysis. Updates Surg 2021; 73: 419-427
• 6 Croome KP, Farnell MB, Que FG. et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches?. Ann Surg 2014; 260: 633-640
• 7 Nickel F, Haney CM, Kowalewski KF. et al. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg 2020; 271: 54-66
• 8 Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the Accordion Severity Grading System. J Am Coll Surg 2012; 215: 810-819
• 9 Song KB, Kim SC, Lee W. et al. Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center. Surg Endosc 2020; 34: 1343-1352
• 10 Gumbs AA, Rodriguez Rivera AM, Milone L. et al. Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol 2011; 18: 1335-1341
• 11 Sukharamwala T, Patel A, Prakash L. et al. Early prediction of pancreatic fistula after pancreatoduodenectomy: a systematic review. World J Surg Oncol 2018; 16: 58
• 12 Tranchart H, Gaujoux S, Rebours V. et al. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy. Ann Surg 2012; 256: 139-145
• 13 Huang H, Wang C, Ji F. et al. Nomogram based on albumin and neutrophil-to-lymphocyte ratio for predicting postoperative complications after pancreaticoduodenectomy. Gland Surg 2021; 10: 877
• 14 Callery MP, Pratt WB, Kent TS. et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg 2013; 216: 1-14
• 15 Lindberg M, Åsberg A, Myrvold H. et al. Reference intervals for procalcitonin and C-reactive protein after major abdominal surgery. Scand J Clin Lab Invest 2002; 62: 189-194
• 16 Giardino A, Spolverato G, Regi P. et al. C-reactive protein and procalcitonin as predictors of postoperative inflammatory complications after pancreatic surgery. J Gastrointest Surg 2016; 20: 1482-1492
• 17 Garcia-Granero A, Frasson M, Flor-Lorente B. et al. Procalcitonin and C-reactive protein as early predictors of anastomotic leak in colorectal surgery: a prospective observational study. Dis Colon Rectum 2013; 56: 475-483
• 18 Zhou Q, Xia Y, Lei Z. The predictive value of procalcitonin for postoperative early pancreatic fistula. BMC Surg 2020; 20: 1-8
• 19 Bassi C, Marchegiani G, Dervenis C. et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2017; 161: 584-591
• 20 Nimptsch U, Krautz C, Weber GF. et al. Nationwide in-hospital mortality following pancreatic surgery in Germany is higher than anticipated. Ann Surg 2016; 264: 1082-1090
• 21 Pedrazzoli S. Pancreatoduodenectomy (PD) and postoperative pancreatic fistula (POPF): a systematic review and analysis of the POPF-related mortality rate in 60,739 patients retrieved from the English literature published between 1990 and 2015. Medicine (Baltimore) 2017; 96: e6858
• 22 Ma J, Jiang P, Ji B. et al. Post-operative procalcitonin and C-reactive protein predict pancreatic fistula after laparoscopic pancreatoduodenectomy. BMC Surg 2021; 21: 171
• 23 Yoo D, Park SY, Hwang DW. et al. Lack of association between postoperative pancreatitis and other postoperative complications following pancreaticoduodenectomy. J Clin Med 2021; 10: 1179
• 24 Lu X, Chen Y. Pathologic assessment of pancreatic fibrosis in predicting pancreatic fistula and management of prophylactic drain removal after pancreaticoduodenectomy. World J Surg 2016; 40: 1520-1521
• 25 Mokart D, Merlin M, Sannini A. et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth 2005; 94: 767-773
• 26 Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 1999; 27: 2172-2176
• 27 Meyer ZC, Schreinemakers JM, de Waal RA. et al. Searching for predictors of surgical complications in critically ill surgery patients in the intensive care unit: a review. Surg Today 2015; 45: 1091-1101
• 28 Sponholz C, Sakr Y, Reinhart K. et al. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006; 10: 1-11
• 29 Gorišek B, Miksić N, Krajnc P. et al. The role of procalcitonin in gynaecological surgery. J Intern Med Res 2009; 37: 918-926
• 30 Iida H, Maehira H, Mori H. et al. Serum procalcitonin as a predictor of infectious complications after pancreaticoduodenectomy: review of the literature and our experience. Surg Today 2020; 50: 87-96
• 31 Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197
• 32 Mintziras I, Maurer E, Kanngiesser V. et al. C-reactive protein and drain amylase accurately predict clinically relevant pancreatic fistula after partial pancreaticoduodenectomy. Int J Surg 2020; 76: 53-58
• 33 Gershov D, Kim S, Brot N. et al. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192: 1353-1364
• 34 Malya FU, Hasbahceci M, Tasci Y. et al. The role of C-reactive protein in the early prediction of serious pancreatic fistula development after pancreaticoduodenectomy. Gastroenterol Res Pract 2018; 2018: 9157806
• 35 Kendrick ML, Cusati D. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. Arch Surg 2010; 145: 19-23
• 36 Vanounou T, Steel JL, Nguyen KT. et al. Comparing the clinical and economic impact of laparoscopic versus open liver resection. Ann Surg Oncol 2010; 17: 998-1009
• 37 Facy O, Paquette B, Orry D. et al. Inflammatory markers as early predictors of infection after colorectal surgery: the same cut-off values in laparoscopy and laparotomy?. Int J Colorectal Dis 2017; 32: 857-863